1. Market Research
  2. > Pharmaceutical Market Trends
  3. > India Pharmaceuticals and Healthcare Report Q3 2015

India Pharmaceuticals and Healthcare Report Q3 2015

  • June 2015
  • -
  • Business Monitor International
  • -
  • 165 pages

Includes 3 FREE quarterly updates

BMI View:

The implementation of universal healthcare in India will remain challenging and we maintain our view that a full nationwide rollout by 2019 is unlikely. This outlook is driven by the low levels of healthcare funding provided by the government as it seeks to reduce budget deficit and prioritise other sectors such as infrastructure. Moreover, we highlight that improvements in healthcare access from the programme will remain weighed on by low levels of medical infrastructure, limiting the commercial opportunities for drugmakers.


Headline Expenditure Projections
Pharmaceuticals: INR1,021bn (USD16.7bn) in 2014 to INR1,154bn (USD18.4bn) by 2015; +13.0% in local currency terms and 11.2% in US dollar terms. Forecast Maintained from previous quarter.
Healthcare: INR5,087bn (USD83bn) in 2014 to INR5,717bn (USD91bn) by 2015; +10.3% in local currency terms and 9.4% in US dollar terms.

Table Of Contents

India Pharmaceuticals and Healthcare Report Q3 2015
BMI Industry View ... 7
SWOT 9
Political . 11
Economic ... 13
Operational Risk . 15
Industry Forecast .. 17
Pharmaceutical Market Forecast 17
Table: Pharmaceutical Sales, Historical Data And Forecasts (India 2011-2019) . 19
Healthcare Market Forecast .. 20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (India 2011-2019) 22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (India 2011-2019) 23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (India 2011-2019) 24
Prescription Drug Market Forecast 25
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (India 2011-2019) 26
Patented Drug Market Forecast . 27
Table: Selected Patent Developments Affecting Drugmakers 28
Table: Patented Drug Market Indicators, Historical Data And Forecasts (India 2011-2019) 30
Generic Drug Market Forecast .. 31
Table: Generic Drug Market Indicators, Historical Data And Forecasts (India 2011-2019) . 32
OTC Medicine Market Forecast . 33
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (India 2011-2019) 34
Pharmaceutical Trade Forecast . 35
Table: Pharmaceutical Trade Data And Forecasts (India 2013-2019) 36
Table: Pharmaceutical Trade Data And Forecasts local currency (India 2013-2019) 37
Key Risks To BMI's Forecast Scenario . 38
Macroeconomic Forecasts ... 39
Economic Analysis ... 39
Table: Services Leading The Charge . 40
Table: Economic Activity (India 2010-2019) . 44
Industry Risk Reward Index . 45
Asia Pacific Risk/Reward Index .. 45
India Risk/Reward Index ... 51
Rewards ... 51
Risks 51
Market Overview ... 52
Industry Trends And Developments 53
Epidemiology 53
Table: Estimated Number Of New Cases Of Cancer In India 54
Healthcare Sector .. 55
Healthcare Sector Developments ... 56
Healthcare Insurance .. 62
Table: Healthcare Resources (India 2009-2014) . 63
Table: Healthcare Personnel (India 2009-2014) . 63
Table: Healthcare Activity (India 2009-2014) 64
Research and Development 64
Table: RandD Expenditure* In Top 20 Indian Pharmaceutical Firms (By Market Capitalisation) (USDmn) 66
Clinical Trials ... 66
Foreign Direct Investment (FDI) ... 70
Biosimilars ... 75
Table: List Of Selected Biosimilars Developed By Indian Pharmaceutical Firms . 78
Traditional Medicines . 78
Regulatory Development .. 80
Pharmaceutical Advertising . 83
Pharmacovigilance . 83
Intellectual Property Regime 84
Table: History Of The Indian Patent System . 85
Table: A Series Of Setbacks For Innovative Pharmaceutical Firms . 86
Pricing Policy ... 90
Compulsory Licences .. 94
Competitive Landscape 95
Table: Ordinary Members Of OPPI 95
Generic Drug Industry 96
Key Industry Developments .. 96
Pharmaceutical Distribution .. 107
Pharmaceutical Retail Sector . 108
Company Profile .. 109
Aurobindo Pharmaceutical .. 109
Cipla ... 113
Dr. Reddy's Laboratories 118
GlaxoSmithKline ... 124
Merck and Co .. 129
Novartis ... 133
Pfizer .. 137
Ranbaxy Laboratories 142
Sanofi India .. 148
Sun Pharmaceutical ... 152
Demographic Forecast ... 154
Table: Population Headline Indicators (India 1990-2025) . 155
Table: Key Population Ratios (India 1990-2025) . 155
Table: Urban/Rural Population And Life Expectancy (India 1990-2025) 156
Table: Population By Age Group (India 1990-2025) 156
Table: Population By Age Group % (India 1990-2025) . 157
Glossary ... 159
Methodology 161
Pharmaceutical Expenditure Forecast Model 161
Healthcare Expenditure Forecast Model ... 161
Notes On Methodology .. 162
Risk/Reward Index Methodology . 163
Index Overview 164
Table: Pharmaceutical Risk/Reward Index Indicators 164
Indicator Weightings 165

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • May 2015
  • by Global Data

PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023 Summary The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the ...

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • May 2015
  • by Global Data

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023 Summary Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible ...

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • May 2015
  • by Global Data

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.